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abstRact
IntroductIon: Patients with localised and locally ad­
vanced renal cancer experience about 20% recurrence dur­
ing a five­year follow­up period. The aim of the present 
study was to report recurrence rates and survival in a Dan­
ish population with renal cancer.
Methods: Data on patients diagnosed with renal cell car­
cin oma (RCC) at our institute from January 2005 to Decem­
ber 2013 were collected retrospectively.
results: Overall, 367 patients were diagnosed with RCC 
during the period, and 78 patients (21%) presented with 
metastasis. The mean follow­up period for all patients was 
41 months (standard deviation = 29, 95% confidence inter­
val: 38­44). The total recurrence rates (RRs) at one, three 
and five years were 4.5%, 13.5% and 22.3%, respectively. 
Overall survival rates in the patients who underwent sur­
gery with localised and locally advanced disease were 
96.1%, 88.2% and 78.3% for one, three and five years, re­
spectively. The mean time to first recurrence was 26.6 
months. The one­year RR was 1.2%, 5.5% and 13.8% for 
low, intermediate and high­risk Leibovich scores, respect­
ively. The three­year RR was 8.3%, 14.1% and 29.6% for 
low, intermediate and high­risk Leibovich scores, respect­
ively; and the five­year RR was 12.0%, 26.6% and 52.9%  
for low, intermediate and high­risk Leibovich scores, re­
spectively.
conclusIons: RRs after localised and locally advanced RCC 
was 22%. According to the risk of recurrence, we recom­
mend a follow­up programme after nephrectomy with com­
puted tomography every second year for low­risk patients, 
annually for intermediate­risk patients and every six 
months for high­risk patients. 
FundIng: none.
trIal regIstratIon: none.
Renal cell carcinoma (RCC) is associated with a signifi­
cantly higher annual mortality­to­incidence ratio than 
any other common urological malignancies [1]. About 
20­30% of all patients have metastatic disease at the 
time of diagnosis [2­4]. In addition, about 20% of the pa­
tients who undergo nephrectomy with a curative intent 
have been shown to develop metastatic RCC (mRCC) 
during follow­up [5, 6]. In most cases, recurrence will 
develop within the first five years after primary surgery 
[7, 8]. Metastatic renal cancer is associated with a poor 
prognosis, and early treatment of the metastasis may 
improve the survival rate [9, 10]. 
The aim of the present study was to report recur­
rence rate (RR) following surgery for localised or locally 
advanced disease and to report cancer­specific survival 
(CSS) and overall survival (OS) in a Danish population 
with renal cancer. 
mEthOds
Data on patients diagnosed with RCC at the Department 
of Urology, Roskilde Hospital, Denmark, from January 
2005 to December 2013 were collected retrospectively 
from patient charts and analysed. We obtained permis­
sion from the Danish Health and Medicines Authority. 
All patients had undergone a computed tomography 
(CT)­urography as well as either a thoracic X­ray or CT as 
part of their diagnostic work­up.
Clinical T­stage was assigned according to the 2009 
TNM classification [11]. Patients who underwent surgery 
before this time were re­classified accordingly by their 
histological features. N0 was assigned to patients with 
no evidence of clinical or pathological involvement of re­
gional lymph nodes, and N1 was assigned when histo­
logical examination of the nephrectomy sample showed 
lymph nodes with malignant cells. M0 was assigned to 
patients with no evidence of clinical or pathological dis­
tant metastasis, and M1 was assigned to patients with 
evidence of clinical or pathological metastasis. None of 
the patients received neoadjuvant treatment in conjunc­
tion with surgery.
Recurrence was defined as tumour relapse in the 
operative field, regional lymph nodes and/or distant  
metastasis as diagnosed either by a CT or histologically 
by biopsies or local resections of metastases. Surgical re­
section status was defined as positive when the tumour 
was described as not radically resected and as negative 
when the tumour was removed radically.
The duration of follow­up was defined as the period 
from diagnosis to last follow­up or death. Data collection 
was performed in January 2015. In order to reduce bias 
in the attribution of cause of death and to clearly distin­
guish between disease­specific death and death from 
other causes, the cause of death was specifically as­
sessed in each deceased individual using the patient 
charts. 
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statistical methods
The RR, CSS and OS were estimated using Kaplan­Meier 
methods. For estimation of RR, patients who were recur­
rence­free at their last date of follow­up or at death 
were censored. Differences in the RR and survival prob­
abilities by various histological features were tested by 
the log­rank test. The multivariable Cox proportional 
hazards ratio (HR) was used to investigate tumour fea­
tures associated with RR, OS and CSS with adjustment 
for age, Leibovich score, presence of sarcomatoid 
growth or metastasis and positive surgical resection. 
Trial registration: none.
REsUlts
Overall, 367 patients were diagnosed with RCC during 
the period, and 78 patients (21%) had metastases at the 
time of diagnosis. The remaining 289 patients presented 
with local or locally advanced renal cancer. The mean 
age was 64 years (range: 37­88 years). Males repre­
sented 238 patients (65%), and females represented 129 
patients (35%). 
Radical nephrectomy was performed in 269 pa­
tients (73.3%, including debulking surgery in 39 patients 
with metastasis), while partial nephrectomy was per­
formed in 59 patients (16.1%). A total of 23 patients 
(6.3%) received oncological treatment only and informa­
tion about the primary treatment was missing for 16 pa­
tients (4.4%). A group of 55 patients (15%) died within 
the first 12 months after diagnosis. The mean follow­up 
period for all patients was 41 months (standard devi­
ation (SD) = 29, 95% confidence interval (CI): 38­44).  
A  total of 52 patients experienced late metastasis within 
five years. Demographic data are shown in table 1. 
tablE 1
The demographic distri­
bution of the data in  
the patients with localized 
and locally advanced  
disease.
Age, mean (± SD) [95% CI], yrs 64 (± 10) [63­65]
Histological classification, n (%)
RCC 229 (79.2)
Papillary   40 (13.9)
Chromophobe   15 (5.2)
Frequency missing     5 (1.7)
Total 289
Pathological tumour stage, n (%)
T1a   97 (33.5)
T1b   66 (22.8)
T2a­T2b   52 (17.9)
T3­T4   69 (23.8)
Frequency missing     5 (1.3)
Total 289
Tumour size, n (%)
≤ 4 cm 111 (38.4)
> 4­7 cm   91 (31.5)
> 7­10 cm   48 (16.6)
> 10 cm   39 (13.5)
Total 289
Fuhrman grade, n (%)
Low grade (I­II)   85 (29.4)
High grade (III­IV) 127 (43.9)
Frequency missing   77 (26.6)
Total 289
Leibovich score, n (%)
Low risk (0­2) 163 (56.4)
Intermediate risk (3­5)   74 (25.6)
High risk (> 5)   52 (17.9)
Total 289
Necrosis, n (%)
No necrosis 130 (44.9)
Necrosis 159 (55.0)
Total 289
Sarcomatoid, n (%)
Not sarcomatoid 277 (95.8)
Sarcomatoid   12 (4.1)
Total 289
Lymph nodes, n (%)
Lymph nodes­positive   10 (3.4)
Lymph nodes­negative 279 (96.5)
Total 289
Surgical resection status, n (%)
Negative resection 276 (95.5)
Positive resection   13 (4.4)
Total 289
Number of sites of recurrence, n (%)
1 27 (51.9)
2 18 (34.6)
3   3 (5.7)
≥ 4   4 (7.6)
Total 52
Year of diagnosis, n (%)
2005­2007   59 (20.4)
2008­2010   90 (31.2)
2011­2013 139 (48.1)
Frequency missing     1 (0.3)
Total 289
Treatment of recurrences, n (%)
No treatment   3 (5.7)
Oncological 27 (51.9)
Surgical 22 (42.4)
Total 52
CI = confidence interval; RCC = renal cell carcinoma; SD = standard  
deviation.
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Univariate analysis
Recurrence rates
RR was calculated in the 289 patients who underwent 
surgery for localised or locally advanced disease. The  
total RRs at one, three, and five years were 4.5%, 13% 
and 22%, respectively. The mean time to first recurrence 
was 26.6 months (SD = 20, 95% CI: 20.9­32.1). Advanced 
T­stage was a significant predictor of recurrence with HR 
13.5 (standard error (SE) = 0.6, 95% CI: 4.1­44.8, p < 
0.0001), HR = 7.1 (SE = 0.63, 95% CI: 2.1­25.1, p = 0.002), 
and HR = 3.9 (SE = 0.67, CI: 1.04­14.9, p = 0.04) for T­
stage (T3­T4), T2 stage (T2a­T2b), and T1b compared 
with stage T1a, respectively. A high Fuhrman grade (III­
IV) was a significant predictor of recurrence compared 
with a low Fuhrman grade (I­II) with a HR = 2.1 (SE = 
0.32, 95% CI: 1.2­4.2, p = 0.16). Presence of sarcomatoid 
growth and necrosis were significant predictors of recur­
rences, with HR = 5.7 (SE = 0.44, 95% CI: 2.4­13.8, p < 
0.0001), and HR = 3.0 (SE = 0.29, 95% CI: 1.7­5.5, p = 
0.0001), respectively. A tumour size between 7 and 10 
cm and more than 10 cm were significant poor predic­
tors of recurrence compared with a tumour size of less 
than 4 cm, HR = 3 (SE = 0.42, 95% CI: 1.4­7, p = 0.005) 
and HR = 4.6 (SE = 0.42, 95% CI: 2.0­10.5, p = 0.0003),  
respectively. Presence of metastasis to the lymph nodes 
(N1) and positive surgical margins were also significant 
predictors of recurrences, HR = 4.9 (SE = 0.4, 95% CI: 2.1­
11.6, p = 0.0002) and HR = 5 (SE = 0.3, 95% CI: 2.3­10.8, 
p < 0.0001), respectively. Patients with high­ and inter­
mediate­risk Leibovich scores had significantly higher 
RRs than patients with a low­risk Leibovich score, HR = 
5.7 (SE = 0.33, 95% CI: 2.9­10.9, p < 0.0001) and HR = 2.2 
(SE = 0.36, 95% CI: 1­4.5, p = 0.027), respectively.
One­year RRs were 1.2%, 5.5% and 13.8% for low, 
intermediate and high­risk Leibovich scores, respective­
ly. Three­year RRs were 8.3%, 14.1% and 29.6% for low, 
intermediate and high­risk Leibovich scores, respective­
ly, and five­year RRs were 12%, 26.6% and 52.9% for 
low, intermediate and high­risk Leibovich scores, re­
spect ively (Figure 1). 
Overall survival
OS rates in patients who underwent surgery for localised 
and locally advanced disease were 96.1%, 88.2% and 
78.3% for one, three and five years, respectively.
The OS rates for all patients with renal cancer were 
85%, 75% and 66% for one, three and five years, re­
spect ively (Figure 2). Primary metastatic disease and late 
metastasis were signs of a poor prognosis. The OS rates 
for patients with primary metastasis were 42%, 26% and 
18% for one, three and five years, respectively; and 94%, 
71% 44% for patients with late metastasis. Primary me­
tastasis increased the risk of dying by HR = 16.4 (SE = 
0.23, 95% CI: 10.2­26.6, p < 0.0001), while late metasta­
sis increased the risk of dying by HR = 4.7 (SE = 0.24, 95% 
CI: 2.7­8.1, p < 0.0001).
Advanced T­stage tumours (T3­T4) increased the risk 
of dying by HR = 4 (SE = 0.32, 95% CI: 2­7.4, p < 0.0001) 
compared with T1 tumour stage. A high Fuhrman grade, 
a tumour size of more than 10 cm, presence of sarco­
matoid growth, positive lymph nodes and positive sur ­
gical margins all increase the risk of dying by HR = 2.4  
(SE = 0.28, 95% CI: 1.4­4.1, p = 0.0016), HR = 2 (SE = 0.25, 
95% CI: 1.2­3.2, p = 0.006), HR = 2.3 (SE = 0.29, 95% CI: 
1.3­4.2, p = 0.003), HR = 3.4 (SE = 0.23, 95% CI: 2.1­5.4,  
p < 0.0001) and HR = 2.3 (SE = 0.33, 95% CI: 1.2­4.4, p = 
0.01), respectively. 
FigURE 1
Impact of Leibovich scores on recurrence rate.  
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Cancer-specific survival
The CSS in patients who underwent surgery for localised 
and locally advanced disease were 99.3%, 99.3 and 
98.9% for one, three and five years, respectively. 
The CSS rates for all patients with renal cancer were 
88%, 82% and 74% for one, three and five years, re­
spect ively. Metastatic disease and late metastasis were 
signs of a poor CSS. CSS rates for patients with primary 
metastasis were 47%, 36% and 31% for one, three and 
five years, respectively; and 96%, 74% and 46% for pa­
tients with late metastasis. The impact of other features 
is described in table 2.
multivariate analysis
Leibovich score (p < 0.0001), presence of sarcomatoid 
growth (p = 0.0011) and the status of surgical margins  
(p = 0.0034) were all significant, independent predictors 
of recurrence, while patients’ age at the time of diagno­
sis was not. Age (p = 0.007), presence of sarcomatoid 
growth (p = 0.51) and metastasis (p < 0.0001) continued 
to be significant and independent predictors of a poor 
OS, while age (p = 0.0204) and status of metastasis 
 (p < 0.0001) were the only significant and independent 
predictors of a poor CSS (table 3).
discUssiOn
We reported Danish data on renal cancer patients and 
investigated the RR, OS and CSS. RR increased, while OS 
and CSS decreased with advanced pathological features 
in both univariate and multivariate analyses. This trend 
has been described before [12]. 
In our cohort, the RRs within five years following 
surgery for non­metastatic renal cancer was 22%. This 
rate is comparable to the international reports, where 
the RRs in the past two decades decreased from 30% to 
20% [5, 6]. This may be owed to the early detection of 
renal tumours as well as to the proper treatment of  
renal cancer patients in our institution. The CSS of 98.9% 
that we observed at five­year follow­up for localised and 
locally advanced disease was higher than reported in the 
literature, which may be owed to considerable develop­
ment in the surgical and anesthesiological techniques in 
the past decade [13]. 
Patients in the high Leibovich risk group had RRs of 
52.9% at five years. For comparison, a study from 1999 
reported a five­year RR of 93% in such patients [8]. This 
difference can likely be attributed to the improvements 
in treatment, which have been developed over the past 
few decades.
Metastatic disease at first presentation was present 
in 78 patients (21%) of 367 patients in this study, which 
is comparable to recent studies [2­4]. This relatively low 
proportion may be owed to early detection of renal can­
cer because of the increase in the use of CT.
tablE 2
Differences in the cancer­specific survival probabilities by various histological features tested by the log­
rank test.
Estimate (standard error) 
[p-valuea]
hazard ratio  
(95% confidence limits)
Metastasis
Non­metastasis Reference
Late metastasis 2.5 (0.4) [< 0.0001] 13.2 (5.9­29.7)
Primary metastasis 3.6 (0.4) [< 0.0001] 40.4 (18.8­86.7)
T-stage
T1a Reference
T1b 0.3 (0.7) [0.6616] 1.3 (0.3­5.4)
T2a­T2b 1.2 (0.5) [0.0319] 3.5 (1.1­11.3)
T3­T4 2.2 (0.5) [< 0.0001] 9.4 (3.3­26.6)
Fuhrman grade
Low Reference 
High 1.1 (0.3) [0.0017] 3.1 (1.5­6.3)
Tumour size
≤ 4 cm Reference  
> 4­7 cm 0.1 (0.3) [0.7988] 0.9 (0.5­1.7)
> 7­10 cm 0.4 (0.3) [0.2241] 1.4 (0.7­2.7)
> 10 cm 0.9 (0.3) [0.0030] 2.5 (1.3­4.5)
Sarcoma
No sarcoma Reference  
Sarcoma 0.9 (0.3) [0.0056] 2.6 (1.3­5.0)
Lymph nodes
Lymph nodes negative Reference  
Lymph nodes positive 1.1 (0.3) [< 0.0001] 3.2 (1.8­5.6)
Necrosis
No necrosis Reference  
Necrosis 0.3 (0.2) [0.2158] 1.3 (0.8­2.0)
Surgical resection
Surgical resection negative Reference  
Surgical resection positive 0.8 (0.4) [0.0349] 2.3 (1.0­5.0)
a) p < 0.05 considered significant.
tablE 3
Multivariate analysis on recurrence rate, overall survival, and cancer­specific survival with control for pa­
tients’ age, Leibovich risk, metastasis status, sarcoma, and surgical resection status.
Estimate (standard error)  
[p-valuea]
hazard ratio  
(95% confidence limits)
Recurrence rate
Age 0.01 (0.01) [0.4568] 1.0 (0.9­1.0)
Leibovich risk 0.6 (0.1) [< 0.0001] 1.9 (1.4­2.7)
Sarcoma 1.5 (0.4) [0.0011] 4.5 (1.8­11.4)
Surgical resection 1.2 (0.4) [0.0034] 3.3 (1.4­7.5)
Overall survival
Age 0.02 (0.01) [0.0071] 1.0 (1.0­1.0)
Sarcoma 0.6 (0.3) [0.0505] 1.8 (0.9­3.3)
Surgical resection 0.3 (0.3) [0.2918] 1.4 (0.7­2.9)
Metastatic status 0.7 (0.1) [< 0.0001] 2.1 (1.7­2.7)
Cancer-specific survival
Age 0.02 (0.01199) [0.0204] 1.0 (1.0­1.0)
Sarcoma 0.5 (0.35134) [0.1066] 1.7 (0.8­3.5)
Surgical resection 0.2 (0.42832) [0.6153] 1.2 (0.5­2.8)
Metastatic status 1.02 (0.13534) [< 0.0001] 2.7 (2.1­3.6)
a) p < 0.05 considered significant.
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In total, three­ and five­year OS rates for all patients 
with RCC regardless of treatment modality were 75% 
and 66%, respectively, which is comparable to interna­
tional reports. OS deteriorated when patients had me­
tastasis at the time of diagnosis or later. This is also in 
accordance with the existing literature [14]. 
The number of patients diagnosed with small renal 
tumours and low­risk disease according to the Leibovich 
score represented half of the cohort. The RRs for these 
patients were significantly lower than in the intermedi­
ate and high­risk cohorts. The increased number of inci­
dental detection of small renal tumours is associated 
with increased use of CT in the past decade [2­4, 15]. 
The Leibovich risk score system is used to stratify 
the risk of recurrence according to histological features, 
and the system was validated externally in many studies 
[15­18] . Therefore, follow­up after renal cancer surgery 
is guided by the Leibovich risk system in Denmark. Be­
cause the survival of patients may improve with early 
detection and treatment of recurrences, we believe that 
the goal is to check for recurrence in patients with a risk 
of 5% or more. In order to achieve this, we recommend 
that patients with a low Leibovich risk receive follow­up 
every second year, while the cohort with intermediate 
Leibovich risk receive follow­up annually. Patients with a 
high Leibovich risk should undergo follow­up every six 
months (see Figure 1). As we only investigated the RR 
within the five­year period following diagnosis, our  
recommendation is limited to this time period. Other 
studies have reported the on RR after renal cancer even 
later, up to ten years [13].
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